Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: Exploratory analysis of the JCOG0303 study

Yasuo Hamamoto; Junki Mizusawa; Hiroshi Katayama; Kenichi Nakamura; Ken Kato; Yasuhiro Tsubosa; Satoshi Ishikura; Hiroyasu Igaki; Masayuki Shinoda; Haruhiko Fukuda; Yuko Kitagawa; Nobutoshi Ando

doi:10.1093/jjco/hyv211

Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: Exploratory analysis of the JCOG0303 study

Yasuo Hamamoto, Junki Mizusawa, Hiroshi Katayama, Kenichi Nakamura, Ken Kato, Yasuhiro Tsubosa, Satoshi Ishikura, Hiroyasu Igaki, Masayuki Shinoda, Haruhiko Fukuda, Yuko Kitagawa, Nobutoshi Ando

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

It is important to examine variation in the treatment effects of patients with esophageal cancer in order to generalize treatment outcomes.We aimed to investigate the range of prognostic differences among hospitals in the treatment of locally advanced esophageal cancer. The JCOG0303 study compared the efficacy of radiotherapy plus low-dose cisplatin and 5-fluorouracil with that of high-dose cisplatin and 5-fluorouracil for unresectable esophageal cancer. Of 32 institutions participating in the JCOG0303 study, the 18 institutions that enrolled three or more patients were included in this study. We predicted the 1-year survival in each institution by using a mixed-effect model.We found that the predicted 1-year survival in the 18 institutions with three ormore patientswas amedian of 60.9%,with a range of 60.9-60.9%. This study is the first to investigated heterogeneity of survival in patients who received definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.

Original language	English
Pages (from-to)	389-392
Number of pages	4
Journal	Japanese journal of clinical oncology
Volume	46
Issue number	4
DOIs	https://doi.org/10.1093/jjco/hyv211
Publication status	Published - 2016 Apr 1

Keywords

Chemoradiotherapy
Esophageal cancer
Heterogeneity

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jjco/hyv211

Cite this

Hamamoto, Y., Mizusawa, J., Katayama, H., Nakamura, K., Kato, K., Tsubosa, Y., Ishikura, S., Igaki, H., Shinoda, M., Fukuda, H., Kitagawa, Y., & Ando, N. (2016). Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: Exploratory analysis of the JCOG0303 study. Japanese journal of clinical oncology, 46(4), 389-392. https://doi.org/10.1093/jjco/hyv211

Hamamoto, Y, Mizusawa, J, Katayama, H, Nakamura, K, Kato, K, Tsubosa, Y, Ishikura, S, Igaki, H, Shinoda, M, Fukuda, H, Kitagawa, Y & Ando, N 2016, 'Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: Exploratory analysis of the JCOG0303 study', Japanese journal of clinical oncology, vol. 46, no. 4, pp. 389-392. https://doi.org/10.1093/jjco/hyv211

@article{a48ebca420d040dfb45199082ab25388,

title = "Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: Exploratory analysis of the JCOG0303 study",

abstract = "It is important to examine variation in the treatment effects of patients with esophageal cancer in order to generalize treatment outcomes.We aimed to investigate the range of prognostic differences among hospitals in the treatment of locally advanced esophageal cancer. The JCOG0303 study compared the efficacy of radiotherapy plus low-dose cisplatin and 5-fluorouracil with that of high-dose cisplatin and 5-fluorouracil for unresectable esophageal cancer. Of 32 institutions participating in the JCOG0303 study, the 18 institutions that enrolled three or more patients were included in this study. We predicted the 1-year survival in each institution by using a mixed-effect model.We found that the predicted 1-year survival in the 18 institutions with three ormore patientswas amedian of 60.9%,with a range of 60.9-60.9%. This study is the first to investigated heterogeneity of survival in patients who received definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.",

keywords = "Chemoradiotherapy, Esophageal cancer, Heterogeneity",

author = "Yasuo Hamamoto and Junki Mizusawa and Hiroshi Katayama and Kenichi Nakamura and Ken Kato and Yasuhiro Tsubosa and Satoshi Ishikura and Hiroyasu Igaki and Masayuki Shinoda and Haruhiko Fukuda and Yuko Kitagawa and Nobutoshi Ando",

note = "Publisher Copyright: {\textcopyright} The Author 2016.",

year = "2016",

month = apr,

day = "1",

doi = "10.1093/jjco/hyv211",

language = "English",

volume = "46",

pages = "389--392",

journal = "Japanese journal of clinical oncology",

issn = "0368-2811",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer

T2 - Exploratory analysis of the JCOG0303 study

AU - Hamamoto, Yasuo

AU - Mizusawa, Junki

AU - Katayama, Hiroshi

AU - Nakamura, Kenichi

AU - Kato, Ken

AU - Tsubosa, Yasuhiro

AU - Ishikura, Satoshi

AU - Igaki, Hiroyasu

AU - Shinoda, Masayuki

AU - Fukuda, Haruhiko

AU - Kitagawa, Yuko

AU - Ando, Nobutoshi

PY - 2016/4/1

Y1 - 2016/4/1

N2 - It is important to examine variation in the treatment effects of patients with esophageal cancer in order to generalize treatment outcomes.We aimed to investigate the range of prognostic differences among hospitals in the treatment of locally advanced esophageal cancer. The JCOG0303 study compared the efficacy of radiotherapy plus low-dose cisplatin and 5-fluorouracil with that of high-dose cisplatin and 5-fluorouracil for unresectable esophageal cancer. Of 32 institutions participating in the JCOG0303 study, the 18 institutions that enrolled three or more patients were included in this study. We predicted the 1-year survival in each institution by using a mixed-effect model.We found that the predicted 1-year survival in the 18 institutions with three ormore patientswas amedian of 60.9%,with a range of 60.9-60.9%. This study is the first to investigated heterogeneity of survival in patients who received definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.

AB - It is important to examine variation in the treatment effects of patients with esophageal cancer in order to generalize treatment outcomes.We aimed to investigate the range of prognostic differences among hospitals in the treatment of locally advanced esophageal cancer. The JCOG0303 study compared the efficacy of radiotherapy plus low-dose cisplatin and 5-fluorouracil with that of high-dose cisplatin and 5-fluorouracil for unresectable esophageal cancer. Of 32 institutions participating in the JCOG0303 study, the 18 institutions that enrolled three or more patients were included in this study. We predicted the 1-year survival in each institution by using a mixed-effect model.We found that the predicted 1-year survival in the 18 institutions with three ormore patientswas amedian of 60.9%,with a range of 60.9-60.9%. This study is the first to investigated heterogeneity of survival in patients who received definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.

KW - Chemoradiotherapy

KW - Esophageal cancer

KW - Heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=84965052563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965052563&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyv211

DO - 10.1093/jjco/hyv211

M3 - Article

C2 - 26830150

AN - SCOPUS:84965052563

SN - 0368-2811

VL - 46

SP - 389

EP - 392

JO - Japanese journal of clinical oncology

JF - Japanese journal of clinical oncology

IS - 4

ER -

Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: Exploratory analysis of the JCOG0303 study

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this